المؤلفون: Yunjing Zeng, Li Gao, Xiaoqing Luo, Yan Chen, Mustafa H. Kabeer, Xuelian Chen, Andres Stucky, William G. Loudon, Shengwen C. Li, Xi Zhang, Jiang F. Zhong

المصدر: Molecular Oncology, Vol 12, Iss 7, Pp 1004-1011 (2018)

مصطلحات موضوعية: microfluidic, myeloma, risk stratification, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Cytogenetic alterations form the basis for risk stratification for multiple myeloma (MM) and guide the selection of therapy; however, current pathology assays performed on bone marrow samples can produce false‐negatives due to the unpredictable distribution and rarity of MM cells. Here, we report on a microfluidic device used to facilitate CD45 depletion to enhance the detection of cytogenetic alterations in plasma cells (PCs). Bone marrow samples from 48 patients with MM were each divided into two aliquots. One aliquot was subjected to classic flow cytometry and fluorescent in situ hybridization (FISH). The other first went through CD45+ cell depletion, further enriched by microfluidic size selection. The enriched samples were then analyzed using flow cytometry and FISH and compared to those analyzed using the classic method only. Unlike the traditional method, the microfluidic device removed the CD45+ leukocytes and specifically selected PCs from the remaining white blood cells. Therefore, the microfluidic method (MF‐CD45‐TACs) significantly increased the percentage of CD38+/CD138+ cells to 37.7 ± 20.4% (P

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1574-7891Test; https://doaj.org/toc/1878-0261Test

الوصول الحر: https://doaj.org/article/37cbc339debc4b3d8d22d0249ad9611eTest

المؤلفون: Linda M. Liau, Keyoumars Ashkan, David D. Tran, Jian L. Campian, John E. Trusheim, Charles S. Cobbs, Jason A. Heth, Michael Salacz, Sarah Taylor, Stacy D. D’Andre, Fabio M. Iwamoto, Edward J. Dropcho, Yaron A. Moshel, Kevin A. Walter, Clement P. Pillainayagam, Robert Aiken, Rekha Chaudhary, Samuel A. Goldlust, Daniela A. Bota, Paul Duic, Jai Grewal, Heinrich Elinzano, Steven A. Toms, Kevin O. Lillehei, Tom Mikkelsen, Tobias Walbert, Steven R. Abram, Andrew J. Brenner, Steven Brem, Matthew G. Ewend, Simon Khagi, Jana Portnow, Lyndon J. Kim, William G. Loudon, Reid C. Thompson, David E. Avigan, Karen L. Fink, Francois J. Geoffroy, Scott Lindhorst, Jose Lutzky, Andrew E. Sloan, Gabriele Schackert, Dietmar Krex, Hans-Jorg Meisel, Julian Wu, Raphael P. Davis, Christopher Duma, Arnold B. Etame, David Mathieu, Santosh Kesari, David Piccioni, Manfred Westphal, David S. Baskin, Pamela Z. New, Michel Lacroix, Sven-Axel May, Timothy J. Pluard, Victor Tse, Richard M. Green, John L. Villano, Michael Pearlman, Kevin Petrecca, Michael Schulder, Lynne P. Taylor, Anthony E. Maida, Robert M. Prins, Timothy F. Cloughesy, Paul Mulholland, Marnix L. Bosch

المصدر: Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-9 (2018)

مصطلحات موضوعية: Glioblastoma, Immunotherapy, Dendritic cell, Vaccine, Medicine

الوصف: Abstract Background Standard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) to standard therapy for newly diagnosed glioblastoma. Methods After surgery and chemoradiotherapy, patients were randomized (2:1) to receive temozolomide plus DCVax-L (n = 232) or temozolomide and placebo (n = 99). Following recurrence, all patients were allowed to receive DCVax-L, without unblinding. The primary endpoint was progression free survival (PFS); the secondary endpoint was overall survival (OS). Results For the intent-to-treat (ITT) population (n = 331), median OS (mOS) was 23.1 months from surgery. Because of the cross-over trial design, nearly 90% of the ITT population received DCVax-L. For patients with methylated MGMT (n = 131), mOS was 34.7 months from surgery, with a 3-year survival of 46.4%. As of this analysis, 223 patients are ≥ 30 months past their surgery date; 67 of these (30.0%) have lived ≥ 30 months and have a Kaplan-Meier (KM)-derived mOS of 46.5 months. 182 patients are ≥ 36 months past surgery; 44 of these (24.2%) have lived ≥ 36 months and have a KM-derived mOS of 88.2 months. A population of extended survivors (n = 100) with mOS of 40.5 months, not explained by known prognostic factors, will be analyzed further. Only 2.1% of ITT patients (n = 7) had a grade 3 or 4 adverse event that was deemed at least possibly related to the vaccine. Overall adverse events with DCVax were comparable to standard therapy alone. Conclusions Addition of DCVax-L to standard therapy is feasible and safe in glioblastoma patients, and may extend survival. Trial registration Funded by Northwest Biotherapeutics; Clinicaltrials.gov number: NCT00045968; https://clinicaltrials.gov/ct2/show/NCT00045968?term=NCT00045968&rank=1Test; initially registered 19 September 2002

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12967-018-1507-6Test; https://doaj.org/toc/1479-5876Test

الوصول الحر: https://doaj.org/article/7b4a8b2c7d344b0e9344d197a7338b0aTest

المؤلفون: Yunjing Zeng, Li Gao, Xiaoqing Luo, Yan Chen, Mustafa H. Kabeer, Xuelian Chen, Andres Stucky, William G. Loudon, Shengwen C. Li, Xi Zhang, Jiang F. Zhong

المصدر: Molecular Oncology, Vol 15, Iss 1, Pp 317-317 (2021)

مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1574-7891Test; https://doaj.org/toc/1878-0261Test

الوصول الحر: https://doaj.org/article/2386802a4b044bcca561db82c415d401Test

المؤلفون: Linda M. Liau, Keyoumars Ashkan, David D. Tran, Jian L. Campian, John E. Trusheim, Charles S. Cobbs, Jason A. Heth, Michael Salacz, Sarah Taylor, Stacy D. D’Andre, Fabio M. Iwamoto, Edward J. Dropcho, Yaron A. Moshel, Kevin A. Walter, Clement P. Pillainayagam, Robert Aiken, Rekha Chaudhary, Samuel A. Goldlust, Daniela A. Bota, Paul Duic, Jai Grewal, Heinrich Elinzano, Steven A. Toms, Kevin O. Lillehei, Tom Mikkelsen, Tobias Walbert, Steven R. Abram, Andrew J. Brenner, Steven Brem, Matthew G. Ewend, Simon Khagi, Jana Portnow, Lyndon J. Kim, William G. Loudon, Reid C. Thompson, David E. Avigan, Karen L. Fink, Francois J. Geoffroy, Scott Lindhorst, Jose Lutzky, Andrew E. Sloan, Gabriele Schackert, Dietmar Krex, Hans-Jorg Meisel, Julian Wu, Raphael P. Davis, Christopher Duma, Arnold B. Etame, David Mathieu, Santosh Kesari, David Piccioni, Manfred Westphal, David S. Baskin, Pamela Z. New, Michel Lacroix, Sven-Axel May, Timothy J. Pluard, Victor Tse, Richard M. Green, John L. Villano, Michael Pearlman, Kevin Petrecca, Michael Schulder, Lynne P. Taylor, Anthony E. Maida, Robert M. Prins, Timothy F. Cloughesy, Paul Mulholland, Marnix L. Bosch

المصدر: Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-2 (2018)

مصطلحات موضوعية: Medicine

الوصف: Following publication of the original article [1], the authors reported an error in the spelling of one of the author names. In this Correction the incorrect and correct author names are indicated and the author name has been updated in the original publication. The authors also reported an error in the Methods section of the original article. In this Correction the incorrect and correct versions of the affected sentence are indicated. The original article has not been updated with regards to the error in the Methods section.

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12967-018-1552-1Test; https://doaj.org/toc/1479-5876Test

الوصول الحر: https://doaj.org/article/523386e861dd4740aa938b4e7fa9768cTest

المؤلفون: Jordan C. Xu, Anthony J. Vargas, Amy Waunch, David L. Gibbs, James P. Cappon, William G. Loudon, Suresh N. Magge

المصدر: Child's Nervous System. 39:1-4

مصطلحات موضوعية: Pediatrics, Perinatology and Child Health, Neurology (clinical), General Medicine

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::cc8e29ca1fd3b25c08bdd43125300cedTest
https://doi.org/10.1007/s00381-022-05480-0Test

المؤلفون: Junjie Zhang, Qingning Su, William G. Loudon, Katherine L. Lee, Jane Luo, Brent A. Dethlefs, Shengwen Calvin Li

المصدر: Journal of Functional Morphology and Kinesiology; Volume 4; Issue 4; Pages: 71

مصطلحات موضوعية: Qigong, breathing signature, vitality score index, AI Medicine, AI deep learning, immune, inflammation, tissue microenvironment, holistic care, telomerase activity, traditional Chinese medicine (TCM)

الوصف: Rising concerns about the short- and long-term detrimental consequences of administration of conventional pharmacopeia are fueling the search for alternative, complementary, personalized, and comprehensive approaches to human healthcare. Qigong, a form of Traditional Chinese Medicine, represents a viable alternative approach. Here, we started with the practical, philosophical, and psychological background of Ki (in Japanese) or Qi (in Chinese) and their relationship to Qigong theory and clinical application. Noting the drawbacks of the current state of Qigong clinic, herein we propose that to manage the unique aspects of the Eastern ‘non-linearity’ and ‘holistic’ approach, it needs to be integrated with the Western “linearity” “one-direction” approach. This is done through developing the concepts of “Qigong breathing signatures,” which can define our life breathing patterns associated with diseases using machine learning technology. We predict that this can be achieved by establishing an artificial intelligence (AI)-Medicine training camp of databases, which will integrate Qigong-like breathing patterns with different pathologies unique to individuals. Such an integrated connection will allow the AI-Medicine algorithm to identify breathing patterns and guide medical intervention. This unique view of potentially connecting Eastern Medicine and Western Technology can further add a novel insight to our current understanding of both Western and Eastern medicine, thereby establishing a vitality score index (VSI) that can predict the outcomes of lifestyle behaviors and medical conditions.

وصف الملف: application/pdf

العلاقة: Kinesiology and Biomechanics; https://dx.doi.org/10.3390/jfmk4040071Test

الإتاحة: https://doi.org/10.3390/jfmk4040071Test

المؤلفون: Linda M. Liau, Keyoumars Ashkan, Steven Brem, Jian L. Campian, John E. Trusheim, Fabio M. Iwamoto, David D. Tran, George Ansstas, Charles S. Cobbs, Jason A. Heth, Michael E. Salacz, Stacy D’Andre, Robert D. Aiken, Yaron A. Moshel, Joo Y. Nam, Clement P. Pillainayagam, Stephanie A. Wagner, Kevin A. Walter, Rekha Chaudhary, Samuel A. Goldlust, Ian Y. Lee, Daniela A. Bota, Heinrich Elinzano, Jai Grewal, Kevin Lillehei, Tom Mikkelsen, Tobias Walbert, Steven Abram, Andrew J. Brenner, Matthew G. Ewend, Simon Khagi, Darren S. Lovick, Jana Portnow, Lyndon Kim, William G. Loudon, Nina L. Martinez, Reid C. Thompson, David E. Avigan, Karen L. Fink, Francois J. Geoffroy, Pierre Giglio, Oleg Gligich, Dietmar Krex, Scott M. Lindhorst, Jose Lutzky, Hans-Jörg Meisel, Minou Nadji-Ohl, Lhagva Sanchin, Andrew Sloan, Lynne P. Taylor, Julian K. Wu, Erin M. Dunbar, Arnold B. Etame, Santosh Kesari, David Mathieu, David E. Piccioni, David S. Baskin, Michel Lacroix, Sven-Axel May, Pamela Z. New, Timothy J. Pluard, Steven A. Toms, Victor Tse, Scott Peak, John L. Villano, James D. Battiste, Paul J. Mulholland, Michael L. Pearlman, Kevin Petrecca, Michael Schulder, Robert M. Prins, Alton L. Boynton, Marnix L. Bosch

المصدر: JAMA oncology.

مصطلحات موضوعية: Cancer Research, Oncology

الوصف: ImportanceGlioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed.ObjectiveTo investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care (SOC) extends survival among patients with glioblastoma.Design, Setting, and ParticipantsThis phase 3, prospective, externally controlled nonrandomized trial compared overall survival (OS) in patients with newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM) treated with DCVax-L plus SOC vs contemporaneous matched external control patients treated with SOC. This international, multicenter trial was conducted at 94 sites in 4 countries from August 2007 to November 2015. Data analysis was conducted from October 2020 to September 2021.InterventionsThe active treatment was DCVax-L plus SOC temozolomide. The nGBM external control patients received SOC temozolomide and placebo; the rGBM external controls received approved rGBM therapies.Main Outcomes and MeasuresThe primary and secondary end points compared overall survival (OS) in nGBM and rGBM, respectively, with contemporaneous matched external control populations from the control groups of other formal randomized clinical trials.ResultsA total of 331 patients were enrolled in the trial, with 232 randomized to the DCVax-L group and 99 to the placebo group. Median OS (mOS) for the 232 patients with nGBM receiving DCVax-L was 19.3 (95% CI, 17.5-21.3) months from randomization (22.4 months from surgery) vs 16.5 (95% CI, 16.0-17.5) months from randomization in control patients (HR = 0.80; 98% CI, 0.00-0.94; P = .002). Survival at 48 months from randomization was 15.7% vs 9.9%, and at 60 months, it was 13.0% vs 5.7%. For 64 patients with rGBM receiving DCVax-L, mOS was 13.2 (95% CI, 9.7-16.8) months from relapse vs 7.8 (95% CI, 7.2-8.2) months among control patients (HR, 0.58; 98% CI, 0.00-0.76; P P = .03).Conclusions and RelevanceIn this study, adding DCVax-L to SOC resulted in clinically meaningful and statistically significant extension of survival for patients with both nGBM and rGBM compared with contemporaneous, matched external controls who received SOC alone.Trial RegistrationClinicalTrials.gov Identifier: NCT00045968

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b8796e6c2da875f3a6b53843ccf462cTest
https://pubmed.ncbi.nlm.nih.gov/36394838Test

المؤلفون: Cyrus Farzaneh, Yigit S. Guner, William G Loudon, William Q. Duong, Peter T. Yu, David Gibbs, Brittany Sullivan, John Schomberg

المصدر: Journal of Surgical Research. 267:48-55

مصطلحات موضوعية: medicine.medical_specialty, Younger age, Thoracic Injuries, Post discharge, medicine.medical_treatment, Aftercare, Logistic regression, Odds, 03 medical and health sciences, 0302 clinical medicine, Humans, Medicine, Child, Rehabilitation, business.industry, Infant, Patient Discharge, Traumatic injury, Child, Preschool, 030220 oncology & carcinogenesis, Emergency medicine, Wounds and Injuries, Accidental Falls, 030211 gastroenterology & hepatology, Surgery, Morbidity, Skilled Nursing Facility, business, Intracranial Hemorrhages, Pediatric population

الوصف: Unintentional falls are a leading cause of pediatric traumatic injury. This study evaluates clinical outcomes of fall-related injuries in children under the age of 10.The National Trauma Database was queried for children who experienced an unintentional fall. Patients were stratified by age in two groups: 1-5 and 6-10 years old. The primary outcome was post discharge extension of care, defined as transfer to skilled nursing facility or rehabilitation center after discharge from the hospital. Descriptive statistics and a multivariable logistic regression analysis were used to compare the two groups.From 2009 to 2016, a total of 8,277 pediatric patients experienced an unintentional fall, with 93.6% of patients being discharged home. Falls were more common in younger children, with greater odds of post discharge extension of care. Predictors of increased associated risk of extended medical care included intracranial hemorrhage (OR 1.05, 95% CI 1.03-1.06) and thoracic injuries (OR 1.03, 95% CI 1.00-1.1.05) (P0.05). Mortality in pediatric patients suffering unintentional falls was a rare event occurring in 0.7% of cases in children 1-5 years old and 0.4% of children 6-10 years old.The majority of children experiencing an unintentional fall are discharged home, with mortality being very rare. However, younger age is prone to more severe and serious injury patterns. Intracranial hemorrhage and thoracic injury were a predictor of need for extended medical care.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bb12ed40fc6aed4b921788b62762977Test
https://doi.org/10.1016/j.jss.2021.04.036Test

المؤلفون: Jordan C, Xu, Shuichi, Suzuki, Jennifer, Chrislip, Ali, Nael, William G, Loudon

المصدر: Journal of Neurosurgery: Case Lessons. 3

مصطلحات موضوعية: General Medicine

الوصف: BACKGROUND Choroid plexus tumors are rare neoplasms that are typically found in the lateral ventricles. They have infrequently been reported in the third ventricle, and treatment strategies have varied. OBSERVATIONS The authors described a 6-month-old patient who presented with irritability and hypotonia. The patient was found to have a large tumor in the third ventricle with obstructive hydrocephalus. Preoperative angiography revealed a feeding artery from the right medial posterior choroidal artery (MPChA). The feeding artery was effectively embolized, and the patient subsequently received open resection of the tumor. Pathology revealed features consistent with atypical choroid plexus papilloma (CPP). LESSONS Choroid plexus tumors are often hypervascular, which can often make gross total resection (GTR) difficult. Preoperative angiography of tumors identifies feeding vessels, and embolization has the potential to decrease perioperative blood loss and allow for a higher GTR rate. Third ventricular CPPs appear to invariably receive vascular supply from the MPChA, arising from the right posterior cerebral artery. Embolization followed by resection of a choroid plexus tumor in the third ventricle is an effective treatment strategy.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a1528ef90d76f624ff83acca12a7a7eTest
https://doi.org/10.3171/case21516Test

المؤلفون: Long T Vu, Vic Keschrumrus, Xi Zhang, Jiang F Zhong, Qingning Su, Mustafa H Kabeer, William G Loudon, Shengwen Calvin Li

المصدر: PLoS ONE, Vol 10, Iss 5, p e0128504 (2015)

مصطلحات موضوعية: Medicine, Science

العلاقة: http://europepmc.org/articles/PMC4438055?pdf=renderTest; https://doaj.org/toc/1932-6203Test; https://doaj.org/article/de44717e6ec640a8a22b25746ab6f07aTest

الإتاحة: https://doi.org/10.1371/journal.pone.0128504Test
https://doaj.org/article/de44717e6ec640a8a22b25746ab6f07aTest